Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide

PHASE2RecruitingINTERVENTIONAL
Enrollment

640

Participants

Timeline

Start Date

May 10, 2024

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2028

Conditions
Glioblastoma, IDH-wildtype
Interventions
DRUG

Metformin

Metformin 2000 to 3000mg/day daily will be started by 6 weeks after histological diagnosis and 7 days before the start of RT-TMZ and will continue until progression.

RADIATION

Radiation IMRT

2 Gy x 5 days for 6 weeks to be started 7 days after first administration of Metformin and by 7 weeks after histological diagnosis

DRUG

Temozolomide

75 mg/m² daily from first to last day of radiation (IMRT) and then 150 to 200 mg/m² x 5 days every 28 days cycle for 12 cycles

Trial Locations (7)

13354

RECRUITING

Timone Hospital, Marseille

20131

NOT_YET_RECRUITING

Istituto Nazionale Carlo Besta, Milan

57100

NOT_YET_RECRUITING

Spidali Riuniti Di Livorno, Livorno

69500

RECRUITING

Hôpital Neurologique Pierre Wertheimer, Bron

75010

RECRUITING

Saint Louis Hospital, Paris

75013

RECRUITING

Pitié Salpêtrière Hospital, Paris

92150

RECRUITING

Foch Hospital, Suresnes

All Listed Sponsors
collaborator

National Cancer Institute, France

OTHER_GOV

lead

Hopital Foch

OTHER